Remedy Selected for Commercialization Project of Radiation System for Cancer Treatment

Prospects for Domestic Production of Expensive Equipment Currently Fully Dependent on Overseas Imports

[Asia Economy Reporter Kim Heeyoon] Remedy, a company specializing in radiation equipment, announced on the 14th that it has been selected for the Ministry of Trade, Industry and Energy's project to "Establish a Commercialization Ecosystem for Image-Guided Radiation Therapy Systems."

This project aims to secure manufacturing technology for radiation therapy systems, build infrastructure, and establish a foundation for the commercialization of radiation therapy systems. Led by Gangwon Technopark and involving Gangwon National University Hospital, Samsung Seoul Hospital, Oncosoft, and Remedy, the project will be carried out over two years with a total budget of 6.84 billion KRW. Remedy has been allocated 4.24 billion KRW of the project funds.

Based on its high-concentration X-ray generation technology platform, Remedy will be responsible for producing prototypes of radiation linear accelerators for cancer treatment and evaluating the performance of the entire radiation therapy system through its accumulated research and development capabilities in radiation medical devices.

Radiation therapy linear accelerators are advanced medical engineering devices for cancer treatment and represent a high value-added medical industry worth nearly 20 billion KRW. However, in South Korea, this technology is entirely imported, resulting in a high dependence on overseas sources. The high difficulty of technology development and the limited number of experts in therapeutic radiation medical devices contribute to this situation. Moreover, the existing clinical demand is concentrated in hospitals, resulting in a domestic radiation therapy linear accelerator penetration rate of about 30%, which is less than half that of advanced countries such as the United States.

A Remedy official stated, "Being selected for this project will accelerate the localization and commercialization of radiation linear accelerators for cancer treatment," adding, "Through our core competencies in radiation therapy technology, we aim to make the radiation cancer treatment field a pillar of K-bio and strive to help patients suffering from cancer worldwide."

This content was produced with the assistance of AI translation services.